MPM BioImpact’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

MPM BioImpact’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-53,279	Closed	-$16.9M	–	43
2023 Q4	$16.9M	Buy	53,279 +69	+0.1%	+$13.4K	3.95%	9
2023 Q3	$9M	Sell	53,210 -189	-0.4%	-$35.5K	2.4%	16
2023 Q2	$11.6M	Buy	+53,399	New	+$11.4M	2.33%	14
2022 Q3	–	Sell	-20,000	Closed	-$2.53M	–	40
2022 Q2	$2.53M	Hold	20,000	–	–	0.7%	30
2022 Q1	$2.54M	Buy	+20,000	New	+$2.25M	0.68%	33

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

MPM BioImpact's KRTX Position: Q1 2024 in Review

MPM BioImpact sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 53,279 shares — an estimated $16.9M sold.

MPM BioImpact first reported a position in KRTX in Q1 2022 and held it in 5 quarters. The position peaked at $16.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

MPM BioImpact reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
MPM BioImpact sold 53,279 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $16.9M.
MPM BioImpact first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
MPM BioImpact's Karuna Therapeutics, Inc. Common Stock position peaked at $16.9M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.